Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.
Australia’s Therapeutic Goods Administration (TGA) has finalised recommendations expanding the Authorized Prescriber (AP) scheme for psilocybin and MDMA. Eligible therapists now include a broader range of health workers; treatment can occur in any medically supervised environment (not just day hospitals); and reimbursement coverage has been extended to public payers (DVA, NDIS, WorkCover) on top of private insurer Medibank. Aggregated real-world data since December 2025 confirm no serious adverse events under the AP scheme.
Optimi already supplies 5 mg psilocybin capsules (treatment‑resistant depression) and 40/60 mg MDMA capsules (PTSD) through this Australian framework via its exclusive distributor Mind Medicine Australia. The updated rules materially broaden the clinical infrastructure and funding for the very therapies Optimi sells.
The 2026‑05‑29 announcement is an incremental, though positive, regulatory progression of an already‑active market. Key facts:
- Optimi’s MDMA and psilocybin have been prescribed in Australia since at least mid‑2025. The framework was always expected to mature; the TGA consultation and anticipated updates were flagged in earlier releases (e.g., 2026‑02‑17 reference to FOI‑obtained safety data, 2026‑02‑26 rollout of psilocybin capsules).
- Today’s expansion of therapist eligibility, treatment settings, and public reimbursement significantly increases the practical addressable patient pool – but does not represent a sudden, unforeseen shift. It is the logical next step of a regulated roll‑out that Australian health authorities had been preparing.
- No revenue figures, patient numbers, or financial guidance were disclosed. The news therefore strengthens the narrative of commercial scaling without yet providing quantifiable proof of near‑term earnings.
- The safety confirmation (no SAEs) removes a potential regulatory overhang and reinforces the case for further insurer/government adoption.
Compared to prior news, the theme is consistent: steady operational progress (shipments, first patient treatments, insurance inclusion) rather than a single game‑changing event. The market had already priced in the broad trajectory, as evidenced by the stock rally from April 2026 lows ($8‑$9) to above $10 after the Ibogaine Initiative and NASDAQ filing. The current decline to ~$7.70 likely reflects a post‑offering digestion, not disappointment with the Australia programme.
Optimi Health is a Health Canada‑licensed, GMP‑compliant manufacturer of pharmaceutical‑grade psychedelic medicines. Its two 10,000‑sq‑ft facilities in British Columbia produce MDMA and psilocybin capsules. The flagship commercial project is the supply of these products to the Australian Authorised Prescriber Scheme — the first nationally regulated access model for psychedelic therapy outside clinical trials. Psilocybin treats treatment‑resistant depression; MDMA treats PTSD. The company also supplies clinical trials (MAPS Israel) and has launched an ibogaine initiative targeting the U.S. market.